2023 World Conference on Lung Cancer (Posters)-P1.25. Outcomes by Age with Neoadjuvant Atezolizumab Treatment for Resectable Non-small Cell Lung Cancer in the Phase 2 LCMC3 Study

P1.25. Outcomes by Age with Neoadjuvant Atezolizumab Treatment for Resectable Non-small Cell Lung Cancer in the Phase 2 LCMC3 Study - PDF(Abstract)

Back to course

Pdf Summary

This abstract presents a subgroup analysis of clinical outcomes by age and T-cell receptor (TCR) repertoire in patients with resectable non-small cell lung cancer (NSCLC) who received neoadjuvant atezolizumab treatment. The study aimed to evaluate the effectiveness and safety of neoadjuvant treatment in patients aged 65 years and older. <br /><br />The study, called LCMC3, included patients with stage IB-IIIA or select IIIB NSCLC. Patients received neoadjuvant atezolizumab for two cycles followed by surgery, and could also receive adjuvant atezolizumab for 12 months. The primary endpoint of the study was a 20% major pathological response (MPR) rate after neoadjuvant atezolizumab. <br /><br />The analysis included 181 enrolled NSCLC patients, with a median T-cell clonality pre-treatment that was significantly lower in patients aged 65 years and older compared to those younger than 65 years. However, after atezolizumab treatment, this trend did not persist. <br /><br />The MPR rate with atezolizumab treatment was found to be similar between the two age groups. In the primary efficacy population, both age groups had a 20% MPR rate. The 3-year overall survival rate was also similar between the age groups. <br /><br />The study identified differences in T-cell clonality and richness between the age groups that warrant further investigation. Numerical differences in toxicities and hospitalization duration were observed between the groups, but there was no significant difference in 3-year overall survival. <br /><br />In conclusion, neoadjuvant atezolizumab treatment for resectable NSCLC showed similar outcomes in terms of MPR rate and overall survival between patients aged 65 years and older and those younger than 65 years. However, differences in T-cell clonality and richness were observed and require further study.

Asset Subtitle

Carolyn Presley

Meta Tag

Speaker Carolyn Presley

Topic Early-Stage NSCLC: Changing Paradigms & Outcomes

Keywords

subgroup analysis

clinical outcomes

age

T-cell receptor

TCR repertoire

resectable non-small cell lung cancer

NSCLC

neoadjuvant atezolizumab treatment

effectiveness

safety